Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Preethi Krishnan

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Antimicrobial Agents and Chemotherapy|August 1, 2018
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical TrialsPreethi Krishnan, Tami Pilot-Matias, Gretja Schnell, et al.
Antimicrobial Agents and Chemotherapy|December 3, 2014
In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5APreethi Krishnan, Jill Beyer, Neeta Mistry, et al.
Genome Medicine|March 22, 2024
Diversity of CFTR variants across ancestries characterized using 454,727 UK biobank whole exome sequencesJustin E Ideozu, Mengzhen Liu, Bridget M Riley-Gillis, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2023
β Cell microRNAs Function as Molecular Hubs of Type 1 Diabetes Pathogenesis and as Biomarkers of Diabetes RiskFarooq Syed, Preethi Krishnan, Garrick Chang, et al.
Injury|May 18, 2025
Understanding social and environmental risks of firearm injury using geospatial patternsSoroosh Noorbakhsh, Will Dunne, Oluwadamilola Babatola, et al.
Antimicrobial Agents and Chemotherapy|November 29, 2017
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in JapanPreethi Krishnan, Gretja Schnell, Rakesh Tripathi, et al.
Antiviral Research|June 15, 2007
Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitroLiangjun Lu, Tatyana Dekhtyar, Sherie Masse, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2017
<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor PibrentasvirTeresa I Ng, Preethi Krishnan, Tami Pilot-Matias, et al.
Nature Medicine|October 15, 2025
Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b studyMoti N Ramgopal, Jacob P Lalezari, Ana Gabriela Pires Dos Santos, et al.
Frontiers in Immunology|November 13, 2023
Distinct functions and transcriptional signatures in orally induced regulatory T cell populationsMoanaro Biswas, Kaman So, Thais B Bertolini, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Antimicrobial Agents and Chemotherapy|August 1, 2018
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical TrialsPreethi Krishnan, Tami Pilot-Matias, Gretja Schnell, et al.
Antimicrobial Agents and Chemotherapy|December 3, 2014
In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5APreethi Krishnan, Jill Beyer, Neeta Mistry, et al.
Genome Medicine|March 22, 2024
Diversity of CFTR variants across ancestries characterized using 454,727 UK biobank whole exome sequencesJustin E Ideozu, Mengzhen Liu, Bridget M Riley-Gillis, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2023
β Cell microRNAs Function as Molecular Hubs of Type 1 Diabetes Pathogenesis and as Biomarkers of Diabetes RiskFarooq Syed, Preethi Krishnan, Garrick Chang, et al.
Injury|May 18, 2025
Understanding social and environmental risks of firearm injury using geospatial patternsSoroosh Noorbakhsh, Will Dunne, Oluwadamilola Babatola, et al.
Antimicrobial Agents and Chemotherapy|November 29, 2017
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in JapanPreethi Krishnan, Gretja Schnell, Rakesh Tripathi, et al.
Antiviral Research|June 15, 2007
Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitroLiangjun Lu, Tatyana Dekhtyar, Sherie Masse, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2017
<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor PibrentasvirTeresa I Ng, Preethi Krishnan, Tami Pilot-Matias, et al.
Nature Medicine|October 15, 2025
Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b studyMoti N Ramgopal, Jacob P Lalezari, Ana Gabriela Pires Dos Santos, et al.
Frontiers in Immunology|November 13, 2023
Distinct functions and transcriptional signatures in orally induced regulatory T cell populationsMoanaro Biswas, Kaman So, Thais B Bertolini, et al.
Pageof 9